This Stock Could EXPLODE 💥 If The FDA Does This

13:05

This Stock Could EXPLODE 💥 If The FDA Does This

Stock Brotha 19.04.2026 3 112 просмотров 359 лайков

Machine-readable: Markdown · JSON API · Site index

Смотреть на YouTube

Поделиться Telegram VK Бот

Транскрипт Скачать .md

Анализ с AI

Описание видео

💸 Click on the link to sign up to the DISCORD for Stock Alerts 🚨 in Real-Time. 👉🏾 WHOP: https://whop.com/stockbrotha 👈🏾 📌 Consider joining my $2.99 YouTube membership and become part of the SBA Family! https://www.youtube.com/channel/UCYMqhQyOB9HvEoIovk-DP1A/join 🏆 *Check out the POSTS section for postings of my Winners | ► https://www.youtube.com/channel/UCYMqhQyOB9HvEoIovk-DP1A/posts* *IG:* https://www.instagram.com/stockbrotha/ *Send your man a gift if I helped you make money with any of my plays* *TIP JAR* 🫙 *VENMO* https://venmo.com/code?user_id=4222775078159459262&created=1734240958 *CASH APP* https://cash.app/$StockBrotha *PAYPAL* https://paypal.me/stockbrotha?country.x=US&locale.x=en_US *BUYMEACOFFEE* https://www.buymeacoffee.com/stockbrotha ✅ *For Potential Sponsorships and Partnerships Only:* *If you are a company or brand interested in sponsoring or partnering with me, email me here: stockbrotha@gmail.com* Discord members will receive Unlimited Real-Time Stock Buy & Sell Alerts 🔔, Access to my Personal Stock portfolio 📈, Unlimited access to All of my Watch Lists, Access to my Stock Catalysts List, Custom Market analysis & Due Diligence (DD) on Stocks, and One-on-One Chat access with Stock Brotha. You will know when I Buy a stock and when I Sell a stock via Real-Time Alerts 🔔 to your phone, laptop, computer, etc. We are all about making money. Let's Get That Paper!!! 💲 💵 In this week's video we discuss: This Stock Could EXPLODE If The FDA Does This We discuss: 🔥 OTLK STOCK 🔥 Outlook Therapeutics, Inc. (Nasdaq: OTLK) Penny Stocks king 👑- Stocks for beginners - How to invest in stocks for beginners #forex #pennystocks #optionstrading ▸▸▸PLEASE SUBSCRIBE AND SMASH THAT LIKE BUTTON: 🙏🏾💪🏾 If you find value in my videos, please make sure to smash that "like" button. I really appreciate your support. Also subscribe to my channel and hit the notification bell so you won’t miss the next hot video. I post at least one video a month where I chronicle my personal journey in the Stock Market and review hot stocks. Let me know your thoughts on this video in the comments section. Thank you very much! HOBBIES: Nursing, Swing Trading, making money, Penny Stocks, and giving back to the community. Favorite Books: Swing Trading as a Part Time Job by Brett Brown and How To Swing Trade by Brian Pezim. Stock Market investing for beginners, how to invest, nifty, Stock Market, Investing money, Finance, Making money in the Stock Market, Trading Stocks, Investment, Stocks Trading, Stock Market, Money and Finance, How to earn positive income, Stock Market trading, wall street, wealth, financial freedom, Stock Market Investing, Penny Stocks, Swing Trade, Swing Trading, Swing Trading For Beginners FAVORITE CHANNELS: Stocks with Josh, Stock Up! with Larry Jones, Kenan Grace, Richard Fain, Stock Moe, Zip Trader, Day Trading Addict, Our Rich Journey, Minority Mindset, Meet Kevin, Andrei Jikh, Graham Stephan, Matthew Perry, ThisisJohnWilliams AFFILIATE DISCLOSURE: Some of the links on this webpage are affiliate links, meaning, at no additional cost to you, I may earn a commission if you click through and make a purchase and/or subscribe. DISCLAIMER: I am not a financial advisor. My videos are for entertainment purposes only and merely cite my own personal journey and opinions. I am not invested into every company I talk about. This Presentation may not be 100% correct, this is for introductory and unofficial material. In order to make the best financial decision that suits your own needs, you must conduct your own research and seek the advice of a licensed financial advisor if necessary. Know that all investments involve some form of risk and there is no guarantee that you will be successful in making money; nor is there any guarantee that you won't experience any loss when investing. Always remember to make smart decisions and do your own research. All commentary is alleged. COPYRIGHT DISCLAIMER: Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. NVDA, AMD, TSLA, DKNG, GME, AMC, TSM, RDDT, TLRY, BB, AAPL, HOOD, FFIE, BTC, BITCOIN, XRP, DOGE, CRYPTO, QUBT, RGTI, FOREX, OPTIONS TRADING, PLTR, QQQ, VOO, SPLG, SCHD, VTI, ETF, REGISTERED NURSE, NURSE, RN, NURSING, OTLK, Outlook Therapeutics, Inc. (Nasdaq: OTLK), FDA

Оглавление (3 сегментов)

Segment 1 (00:00 - 05:00)

This video is for informational and educational purposes only. I am not a licensed financial advisor. Here comes the [singing] money. Here we go. Money talks. Here comes the money. What's going on SBA family? It's your man Stock Brother and I'm back with another one. In this video we are going to be covering a biotech company that is in the middle of a high stakes battle with the FDA that could put a new weapon in doctor's hands to fight wet age-related macular degeneration. The stakes here are high, but if this company can pull this off, the gains would be enormous. I've been loading up on the stock like crazy in anticipation of the outcome of this decision. We're going to be doing a quick review of that company, so stay tuned. Family, before you do anything else, let's get 1,000 likes on this video. Please smash that like button. It helps YouTube push this video to more people — and I would really appreciate your support. So without further ado, let's take care of some business then get right into it. Consider joining the Discord for real-time alerts of all my hot stock picks. It's an affordable service that won't break your pockets. By joining the family, you will be amongst motivated like-minded individuals making money in the stock market. The link is in the description below. Let's get that paper family. Outlook Therapeutics is a commercial stage biopharmaceutical company based in Iceland, New Jersey trading on the Nasdaq under the ticker symbol OTLK. The company has one singular mission and that is to develop and commercialize a better, more standardized version of one of the most widely used retinal drugs in the world, bevacizumab, specifically for the treatment of wet age-related macular degeneration, what the medical world calls wet AMD. Their lead product is called ONS-5010, which in Europe has received full marketing authorization under the brand name Lytenava. We are going to come back to the science of this drug in a moment, but let's first understand what makes this company's position so unique. Lytenava is already approved and commercially available in Europe. Specifically, Germany and the United Kingdom launched first and Austria followed in January the 2026. The company holds 10 years of market exclusivity covering 31 European countries and they have received a positive recommendation from NICE, the UK's top health technology body. Management projects gross peak European sales of over $600 million from the EU rollout alone. — But here in the United States, the story is far more complicated and that is exactly where the most explosive potential and the most risk lives right now. — To understand why ONS-5010 matters, you have to understand wet AMD. Age-related macular degeneration is the leading cause of vision loss in Americans age 65 and older. Nearly 20 million Americans are currently living with some form of AMD. The wet form, which is the more severe and rapidly progressing version, accounts for only about 10% of all AMD cases, but it is responsible for 90% of legal blindness caused by the disease. In wet AMD, abnormal blood vessels grow underneath the macula, the central part of the retina responsible for your sharp, detailed vision. These blood vessels leak fluid and blood causing rapid damage to the cells that let you see faces, red, drive, and recognize color. Without treatment, patients can go from mild blur to legal blindness in a matter of months. Approximately 200,000 new cases of wet AMD are diagnosed every year in North America alone and the number of people with AMD in the United States is expected to more than double between 2010 and 2050, reaching over 5 million. The current standard of care involves injecting anti-VEGF medications directly into the eye, stopping those abnormal blood vessels from growing. This is where bevacizumab comes in and this is where Outlook Therapeutics has carved out its entire reason for existing. Right now, the US anti-VEGF retina market is worth $8. 5 billion per year. Across the country, retina specialists are already using repackaged off-label versions of bevacizumab, the cancer drug Avastin, to treat wet AMD patients. In fact, according to industry data cited in the Outlook investor

Segment 2 (05:00 - 10:00)

presentation, off-label repackaged bevacizumab is the most commonly used first-line anti-VEGF agent in the United States. Used in 55% of first-line cases and in 34% of maintenance cases. There are an estimated 2. 7 million such injections happening every year in the US using a drug that was never specifically approved or formulated for ophthalmic use. That off-label use costs as little as $75 per injection. Branded competitors like Lucentis, Eylea, and Vabysmo can run over $2,000 per injection. Outlook Therapeutics intends to price Lytenava in the US at a point that payers and retina specialists have indicated is reasonable, sitting right in the middle tier of the market competing directly with biosimilar ranibizumab and aflibercept products in the $1,000 to $1,500 range. If approved, Lytenava would be the first and only FDA approved ophthalmic formulation of bevacizumab, manufactured entirely in the United States with standardized production, FDA approved labeling, and robust safety monitoring. — That is a huge deal. Doctors who are currently using a cancer drug off-label would finally have a dedicated approved option that was actually designed and tested specifically for the eye. Now, let's talk about the FDA battle because this is where the story gets complicated and where the stock has been absolutely punished. Outlook conducted a phase three clinical trial called NORSE Two, a 228-patient randomized, double-masked, active controlled study comparing ONS-5010 against ranibizumab, which is Lucentis, the approved standard. In August 2023, the agency issued its first complete response letter or CRL, citing a need for additional confirmatory evidence of efficacy. — The company ran a second trial, NORSE Eight, a 400-patient phase three non-inferiority study. NORSE Eight showed clinically meaningful improvements in visual acuity and dramatic reductions in retinal thickness at every time point. The FDA issued a second CRL in August 2025, again citing lack of substantial evidence of effectiveness. Outlook resubmitted in October 2025. Then on December 30th, 2025 came the third CRL. The same deficiency cited again. The stock then collapsed. Before that, OTLK was trading at its relative highs above $1. 50 and touching as high as $3. 50 at certain points with investor hopes riding on the BLA resubmission. At the time of this recording, the stock was trading at $0. 31. — Ascendant Capital maintains a buy rating with a price target of $6 as of March 2026. The average analyst price target is $3. That implies potential upside of over 1,000% from current levels — if a positive regulatory outcome were to materialize. Now, here is the part of the story that I think most people watching OTLK have completely missed because while Outlook Therapeutics was fighting its third CRL, the FDA itself was quietly rewriting the rules of the game and the timing of that rewrite could not be more relevant to this dispute. On February 18th, 2026, just weeks after that December 30th CRL landed, FDA Commissioner Martin Makary and Vinay Prasad published an article in the New England Journal of Medicine announcing a seismic shift in FDA approval policy. The agency formally abandoned what they called the two trial dogma, the long-standing default requiring two separate, adequate, and well-controlled studies before approving a drug. Under the new default standard, a single pivotal trial combined with confirmatory evidence is now enough. Let me say that again. The FDA has officially stated that one solid clinical trial supported by mechanistic data, pharmacodynamic evidence, or real-world data is now the default bar for drug approval, not two trials, one. Here is where we are right now. On April 7th, 2026, Outlook Therapeutics announced that it had submitted a formal dispute resolution request or FDRR to the FDA as a follow-up to a type A meeting that took place on March 2nd, 2026 and the critical news in that press release is this, the FDA accepted the request and has granted a meeting with

Segment 3 (10:00 - 13:00)

the deciding official to be conducted in April 2026. What exactly is a formal dispute resolution request? Think of it as a formal internal appeal within the FDA. Outlook requested a supervisory review of the disputed scientific position at a level above the team that issued the original decision. This is not a phone call or a casual dialogue. It is a structured process with real process expectations. The FDA deciding official is required to issue either a response or an interim decision within 30 calendar days of the meeting. The core fight has always been the same question. Does the totality of evidence from NORSE 2, NORSE 8, mechanistic pharmacodynamic data, and a consistent safety profile across the clinical trials constitute substantial evidence of effectiveness? CEO Bob Jarrah stated in the April 7th press release that the company believes the data from NORSE 2 and NORSE 8 provides sufficient evidence to support approval. So, what could actually happen in April? The deciding official has real authority and there are four realistic paths. First, the appeal could be denied leaving the FDA's position in place and sending the company back to square one. — Second, the appeal could be granted in full or in part, which would be a meaningful win for the company. Third, an interim response could be issued buying more time for internal review. Fourth, and this is underappreciated, the FDA could provide a clearer roadmap of what confirmatory evidence would actually satisfy the agency's concern even without a reversal. In my opinion, excluding a denial, the other three outcomes could catapult the stock to its previous highs. Outlook Therapeutics has real European revenue, a real product that already has full regulatory approval in 31 countries, a clinical trial that met its primary endpoint with statistical significance, and a safety record that the FDA itself has not questioned. — The fight here is entirely over the evidentiary bar for US approval, not over whether the drug works or whether it hurts patients. I'm excited about the possibilities here, and as I stated before, I've been loading up on the stock. I'm keeping my fingers crossed that we get a positive outcome. That's all that I have for today, family. Thank you for watching. Follow me on Instagram and comment down below. Don't forget to subscribe to the channel and help your man out by smashing that like button. It really helps the video get seen by more people on YouTube. I'll see you all in the Stock Brother Discord. The link for that is down below. So, until next time, let's get that paper.

Другие видео автора — Stock Brotha

Ctrl+V

Экстракт Знаний в Telegram

Экстракты и дистилляты из лучших YouTube-каналов — сразу после публикации.

Подписаться

Лучшие методички за неделю — каждый понедельник